BACKGROUND: Obese patients are frequently characterized by insulin resistance and decreased insulin-mediated glycogen synthesis in skeletal muscle. Whether they also have impaired postprandial hepatic glycogen synthesis remains unknown. AIM: To determine whether postprandial hepatic glycogen synthesis is decreased in obese patients compared to lean subjects. METHODS: Lean and obese subjects with impaired glucose tolerance were studied over 4 h after ingestion of a glucose load. Hepatic uridine diphosphoglucose kinetics were assessed using 13 C-galactose infusion, with monitoring of urinary acetaminophen ± glucuronide isotopic enrichment to estimate hepatic glycogen kinetics. RESULTS: Estimated net hepatic glycogen synthesis amounted to 18.6 and 22.6% of the ingested load in lean and obese subjects, respectively. CONCLUSION: Postprandial hepatic glycogen metabolism is not impaired in non-diabetic obese subjects.
Introduction
The liver plays a central role in the regulation of glucose homeostasis. Output of glucose from the liver is the result of two processes, glycogenolysis and gluconeogenesis. Net hepatic glucose output decreases after ingestion of a carbohydrate meal. This is secondary to several factors: hyperinsulinaemia and a decreased glucagon to insulin ratio in the portal blood directly inhibits glucose output; 1 ± 3 in addition, systemic hyperinsulinaemia inhibits adipose tissue lipolysis and the resulting drop in free fatty acid concentration contributes to suppress glucose output; 4 and hyperglycaemia by itself also inhibits glucose production, possibly through increased glucose and glucose-6-phosphate concentrations in hepatocytes, inhibiting glycogen breakdown. 5, 6 At the same time as glucose output is inhibited, a portion of the ingested carbohydrate load is actually taken up by liver cells, where it is thought to be essentially directed toward replenishment of hepatic glycogen stores. Portal hyperglycaemia and a negative artery to hepatic portal venous glucose gradient are important determinantsofthispostprandialhepaticglucoseuptake. 7 Several observations support the concept that the hepatic glucose metabolism plays a key role in glucose homeostasis. In type 2 diabetes, there is strong evidence that postprandial suppression of glucose production is blunted. 8 In both obese and non-obese patients with impaired glucose tolerance, a lower suppression of glucose production contributes to postprandial hyperglycaemia. 9 There is ample evidence that obese patients frequently have insulin resistance, which is responsible for decreased whole body insulin-mediated glucose storage. 10 It has further been documented that stimulation of skeletal muscle glycogen synthesis is impaired in insulin-resistant obese patients. 11 In contrast, little information is available on postprandial hepatic glucose uptake and glycogen synthesis in these subjects. One study reported that postprandial splanchnic glucose metabolism is not inhibited and may even be increased in obese patients. 12 In order to further address this question, we monitored hepatic glycogen metabolism in lean and obese patients with impaired glucose tolerance after ingestion of a glucose load. Hepatic glycogen synthesis was indirectly assessed by infusion of 1-13 C galactose to label the intrahepatic uridine diphosphoglucose (UDPG) pool and administration of acetaminophen to sample this pool non-invasively. 13 With this method, 13 C galactose is converted into UDP 13 C galactose, then UDP 13 C glucose, and ®nally 13 C glycogen. Since synthesis of UDP glucose from glucose-1-phosphate and UTP is essentially irreversible, 13 the appearance of 13 C glucose in the circulation can be used to assess degradation of newly formed glycogen, and hence glycogen turnover.
Methods

Subjects
Six obese non-diabetic patients and six lean subjects were selected to take part to this study. Lean subjects all had normal glucose tolerance, as assessed from a plasma glucose concentration 2 h after ingestion of a 75 g glucose meal. The experimental protocol described below was approved by the ethical committees of Lausanne and Lie Áge University Schools of Medicine and every participant provided an informed, written consent.
Experimental protocol
Subjects were studied in the morning after an overnight fast. Food records obtained for the 3 days preceding the investigation indicated that they had consumed a diet containing at least 200 g carbohydrate per day.
At their arrival at the metabolic laboratory, subjects were weighed, measured, and their fat mass and fatfree mass were calculated from skinfold thickness measurements 14 (Table 1 ). This technique has been shown to have a fair concordance with underwater weighing, but may lead to some underestimation of fat mass in obese patients. 15 Subjects were thereafter transferred to a bed, and a venous cannula was inserted into a wrist vein of the right arm. The right hand was subsequently placed in a thermostabilized box heated at 55 C to achieve partial arterialization of venous blood. Blood samples were collected from this cannula. A second cannula was inserted into an antecubital vein of the left arm, and primed-continuous infusions of 6,6 2 H-glucose (Masstrace, Worcester, MA; prime: 4 mgakg; continuous: 40 mga(kg min)) and 1-13 C-galactose (Masstrace; prime: 15 mgakg; continuous 3 mga(kg min)) were started at time 0 and continued throughout the 390 min experiment. Oral acetaminophen (Tylenol paediatric drops, Janssen-Cilag, Baar, Switzerland) was administered as 150 mg doses at times À140, À120, À60, 0, 60, 120 and 180 min. After allowing 2 h for tracer equilibration (time À150 to À30 min), two blood samples were taken 30 min apart for determination of basal glucose turnover and plasma hormone and substrate concentrations (time À30 and 0 min). Thereafter (time 0 min), an oral glucose load (1.5 g glucoseakg fat-free mass, dissolved into 300 ml lemon-¯avored water) was ingested over 5 min. Blood samples were taken every 30 min after ingestion of the glucose load until time 240 min for determination of tracer dilution and of hormone and substrate concentrations. In addition, subjects were requested to void at times 150 and 390 min. Urines collected between 150 and 390 min were used for puri®cation of urinary acetaminophen glucuronide.
Analytical procedures. Plasma glucose isotopic enrichments were determined on deproteinized samples partially puri®ed over sequential cation-anion exchange resins (AG 1-X8 and AG 50W-X8, Bio-Rad, Richmond, CA). For 6,6 2 H-glucose measurements, penta-acetyl glucose was analysed with GC-MS (Hewlett Packard, Palo Alto, CA) in chemical ionization mode with selective monitoring of maz 331 and 333. 6 For 13 C-glucose, samples were puri®ed with HPLC on an Aminex HPX-87C column, as described previously, 16 evaporated to dryness, and analysed with continuous-¯ow isotope ratio mass spectrometry (Roboprep CNaTracermass, Europa Scienti®c, Crewe, UK).
Urinary acetaminophen ± glucuronide was puri®ed and glucuronide was converted into glucose, as described by Magnusson et al. 17 To determine the 13 C abundance of glucuronide, the glucose obtained with this procedure was puri®ed and its 13 C enrichment was measured.
Plasma insulin (kit from Biodata SpA, Guidonia Montecelo, Italy), glucagon (kit from Linco Research, St Charles, USA), and C-peptide (kit from Biodata SpA) were measured by radioimmunoassays. Plasma and urine glucose concentrations were measured with a Beckman glucose analyser II (Beckman Instruments, Fullerton, CA).
Calculations. Glucose rates of appearance (GR a ) and disappearance (GR d ) were calculated from plasma 6,6 2 H-glucose using Steele's equations for non-steady state. 18 Metabolic clearance rate of glucose was calculated as GR d divided by plasma glucose concentration. 2 13 C glucose enrichments at time t 1 and t 2 , respectively; 0.2 is the glucose distribution space and 0.75 is the pool fraction. The cumulated amount of glucose released from UDPG was subsequently calculated over 4 h postprandial. Net hepatic UDPG storage was calculated as (hepatic UDPG turnover) À (systemic release of UDPG-derived glucose).
Data analysis. All data obtained were normalized for fat-free mass and were presented as mean AE s.e.m. Between groups comparisons were performed by twoway analysis of variance and unpaired t-tests with Bonferonni's adjustment.
Results
Plasma glucose, insulin and free fatty acid concentrations are shown in Figure 1 . All six obese patients had impaired glucose tolerance. 20 Compared to lean subjects, obese patients had a slight elevation of plasma glucose concentrations during the ®rst 3 h after ingestion of the glucose load. Plasma insulin concentration was higher in the basal state and during the 4 h after ingestion of the load, but plasma free fatty acid concentrations were not markedly altered. Figure 2 shows similar evolution of plasma 6,6 2 H glucose and 13 C 6 glucose enrichment. Glucose rate of appearance was not signi®cantly different in lean and obese subjects but glucose disappearance tended to be lower during the initial 2 h after glucose ingestion in the obese subjects (Figure 3) . Total UDPG turnover, UDPG release and net UDPG storage calculated over the 4 h post-glucose ingestion were similar in lean and obese subjects (Figure 4 ). Total UDPG turnover represented 34.7AE 4.3% of the ingested glucose load in obese patients and 29.7 AE 4.1% in lean subjects. Net UDPG storage, an indirect assessment of net hepatic glycogen synthesis, represented 22.6AE 2.8% of the ingested glucose load in obese patients and 18.6AE 3.0% in lean subjects (NS).
Discussion
There is ample evidence that obese patients have extrahepatic and possibly hepatic insulin resistance, as indicated by decreased insulin-induced glucose uptake and suppression of glucose production. 10 In contrast, obese patients with normal glucose tolerance were reported to have normal suppression of glucose Postprandial hepatic glycogen synthesis in obese N Paquot et al production after ingestion of a standardized glucose meal. 9 We extend these observations by showing that the UDPG kinetics of obese patients with impaired glucose tolerance do not differ from that of non-obese subjects, suggesting that their postprandial hepatic glycogen metabolism was not abnormal. The use of 13 C-labelled galactose and acetaminophen to respectively label and sample the intrahepatic UDPG pool has been extensively discussed by Hellerstein et al. 13, 19 It rests on several assumptions. The ®rst of these assumptions is that 13 C galactose is exclusively metabolized in liver cells where it is converted into galactose-1-phosphate, uridine-diphosphogalactose and UDPG. This assumption appears essentially veri®ed in man under most conditions tested. The second assumption is that monitoring of the enrichment of glucuronic acid excreted into the urine as acetaminophen glucuronide accurately re¯ects that of the intrahepatic UDPG pool. This assumption of course is hardly directly veri®able in man. It has been shown that acetaminophen glucuronide changes rapidly upon nutrient administration in man, and that there is a short lag time between changes in acetaminophen enrichment in blood and in urine. 13 Since glucuronic acid is directly issued from the UDPG pool, it appears a reasonable substitute to estimate the isotopic enrichment of the latter, assuming that UDPG turnover and glucuronidation of xenobiotics occurs uniformly in all hepatic cells.
UDPG kinetics provide a way to assess non-invasively intrahepatic glycogen kinetics. Glycogen synthesis proceeds with conversion of glucose-6-phosphate to glucose-1-phosphate, and then to UDPG. Although these reactions appear reversible according to thermodynamic considerations, synthesis of UDPG occurs with conversion of 1 mol of UTP to UMP and pyrophosphate, the latter being immediately and irremediably degraded into inorganic phosphates in the pyrophosphate reaction. Hence the synthesis of UDPG from glucose-1-phosphate is virtually irreversible. Since the bulk of UDPG is further converted into hepatic glycogen, monitoring of UDPG turnover is therefore expected to provide a fair estimate of hepatic glycogen synthesis. In support of this hypothesis, data from Hellerstein's laboratory as well as our own data indicate that UDPG turnover increases signi®cantly in healthy subjects during the fasting to fed transition. 19, 21 Interestingly, part of the 13 C label infused as 13 C galactose recirculated as glucose in the time course of the experiment. In the light of the considerations mentioned above, it appears very unlikely that this 13 C glucose synthesis corresponds to direct conversion of UDPG into glucose-6-phosphate. It has been documented in healthy humans that both hepatic glycogen synthesis and breakdown occur simultaneously in healthy humans after glucose administration. 22 It is therefore likely that plasma 13 C glucose appearance re¯ects the breakdown of newly formed, labelled glycogen. Subtraction of the amount of this 13 C-labelled glucose recirculating after Postprandial hepatic glycogen synthesis in obese N Paquot et al having transited in the hepatic glycogen pool from UDPG turnover (the latter calculated from the dilution of infused 13 C galactose in the UDPG pool) provides an estimate of net intrahepatic UDPG deposition, or net glycogen synthesis. The values obtained in our healthy subjects demonstrate that about 18% of the ingested glucose load was deposited over 4 h after ingestion of a glucose load. This value is in close agreement with the estimate reported in healthy humans using in vivo hepatic nuclear magnetic resonance spectroscopy. 23, 24 Our obese patients had modest postprandial hyperglycaemia and marked hyperinsulinaemia compared to healthy subjects over the 4 h following ingestion of a glucose load. They also had an impaired stimulation of glucose utilization, suggesting muscle insulin resistance, a ®nding frequently demonstrated in this population. 25 In contrast, their postprandial UDPG kinetics were similar to that observed in lean subjects, indicating normal hepatic glycogen turnover and net hepatic glycogen synthesis. Data regarding postprandial hepatic glycogen synthesis in human obese patients are scarce. Ludvik et al 12 recently measured postprandial splanchnic glucose uptake in obese and lean humans both by hepatic catheterization and the oral ± i.v. glucose clamp technique. The latter consisted of the administration of a glucose load in the course of a hyperinsulinaemic clamp which nearly completely suppressed endogenous glucose output; in these conditions, the difference between the cumulated reduction in the glucose infusion required to maintain euglycaemia and the amount of glucose ingested provides an estimate of splanchnic glucose uptake. With both approaches it was concluded that postprandial splanchnic glucose uptake was increased in obese patients. 12 The present data corroborate that there is no indication for a reduced postprandial hepatic glycogen synthesis in obese patients with normal glucose tolerance. They therefore suggest that the mechanisms which interfere with insulin-mediated glycogen synthesis in skeletal muscle are not operative in liver cells. It remains possible, however, that hyperinsulinaemia and moderate hyperglycaemia present in obese patients stimulated glycogen synthesis, which would have possibly been decreased at plasma insulin and glucose concentrations similar to those observed in healthy subjects. In addition, our data give only an estimate of hepatic glycogen metabolism cumulated over 4 h after ingestion of a glucose load. It cannot be excluded that hepatic glycogen synthesis had different time courses in obese and lean subjects.
In conclusion, our data indicate that postprandial hepatic glycogen metabolism is not altered in insulinresistant obese patients with impaired glucose tolerance. This suggests that insulin resistance secondary to obesity impairs glycogen synthesis predominantly in skeletal muscle, but little in liver cells.
